Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1048743

Cover Image

PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1048743

Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2032

Published: Pre-Order
PAGES: 60 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (Site License)
USD 7900
PDF (Global License)
USD 11850

Add to Cart

DelveInsight's "Glioblastoma Multiforme (GBM) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Glioblastoma Multiforme (GBM) Understanding

The DelveInsight Glioblastoma Multiforme (GBM) epidemiology report gives a thorough understanding of the Glioblastoma Multiforme (GBM) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Glioblastoma Multiforme (GBM) in the US, Europe, and Japan. The report covers the detailed information of the Glioblastoma Multiforme (GBM) epidemiology scenario in seven major countries (US, EU5, and Japan).

Glioblastoma Multiforme (GBM) Epidemiology Perspective by DelveInsight

The Glioblastoma Multiforme (GBM) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Glioblastoma Multiforme (GBM) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Glioblastoma Multiforme (GBM) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Glioblastoma Multiforme (GBM) Detailed Epidemiology Segmentation

The Glioblastoma Multiforme (GBM) epidemiology covered in the report provides historical as well as forecasted Glioblastoma Multiforme (GBM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Glioblastoma Multiforme (GBM) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Glioblastoma Multiforme (GBM) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Glioblastoma Multiforme (GBM) Epidemiology Report and Model provide an overview of the global trends of Glioblastoma Multiforme (GBM) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Glioblastoma Multiforme (GBM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Glioblastoma Multiforme (GBM)
  • The report provides the segmentation of the Glioblastoma Multiforme (GBM) epidemiology

Report Highlights:

  • 11-year Forecast of Glioblastoma Multiforme (GBM) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Glioblastoma Multiforme (GBM)
  • Cases of Glioblastoma Multiforme (GBM) by Mutation Types
  • Glioblastoma Multiforme (GBM) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Glioblastoma Multiforme (GBM)?
  • What are the key findings pertaining to the Glioblastoma Multiforme (GBM) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Glioblastoma Multiforme (GBM) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Glioblastoma Multiforme (GBM)?
  • What are the currently available treatments of Glioblastoma Multiforme (GBM)?

Reasons to buy:

The Glioblastoma Multiforme (GBM) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme (GBM) market
  • Quantify patient populations in the global Glioblastoma Multiforme (GBM) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Glioblastoma Multiforme (GBM) therapeutics in each of the markets covered
  • Understand the magnitude of Glioblastoma Multiforme (GBM) population by its epidemiology
  • The Glioblastoma Multiforme (GBM) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Product Code: DIEI0292

Table of Contents

1. Key Insights

2. Executive Summary of Glioblastoma Multiforme (GBM)

3. Glioblastoma Multiforme (GBM): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in the 7MM (2019- 2032)
  • 5.4. United States Epidemiology
    • 5.4.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in the United States (2019- 2032)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in Germany (2019- 2032)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in France (2019- 2032)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in Italy (2019- 2032)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in Spain (2019- 2032)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in the United Kingdom (2019-2032)
  • 5.6. Japan Epidemiology
    • 5.6.1. Glioblastoma Multiforme (GBM) Epidemiology Scenario in Japan (2019- 2032)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Glioblastoma Multiforme (GBM) Treatment and Management
  • 6.2. Glioblastoma Multiforme (GBM) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

  • The table of contents is not exhaustive; will be provided in the final report
Product Code: DIEI0292

List of Tables

List of Table:

  • Table 1: Glioblastoma Multiforme (GBM) Epidemiology in 7MM (2019-2032)
  • Table 2: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in 7MM (2019-2032)
  • Table 3: Glioblastoma Multiforme (GBM) Epidemiology in the United States (2019-2032)
  • Table 4: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in the United States (2019-2032)
  • Table 5: Glioblastoma Multiforme (GBM) Epidemiology in Germany (2019-2032)
  • Table 6: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Germany (2019-2032)
  • Table 7: Glioblastoma Multiforme (GBM) Epidemiology in France (2019-2032)
  • Table 8: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in France (2019-2032)
  • Table 9: Glioblastoma Multiforme (GBM) Epidemiology in Italy (2019-2032)
  • Table 10: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Italy (2019-2032)
  • Table 11: Glioblastoma Multiforme (GBM) Epidemiology in Spain (2019-2032)
  • Table 12: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Spain (2019-2032)
  • Table 13: Glioblastoma Multiforme (GBM) Epidemiology in the United Kingdom (2019-2032)
  • Table 14: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
  • Table 15: Glioblastoma Multiforme (GBM) Epidemiology in Japan (2019-2032)
  • Table 16: Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Japan (2019-2032)

List of Figures

List of Figures

  • Figure 1 Glioblastoma Multiforme (GBM) Epidemiology in 7MM (2019-2032)
  • Figure 2 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in 7MM (2019-2032)
  • Figure 3 Glioblastoma Multiforme (GBM) Epidemiology in the United States (2019-2032)
  • Figure 4 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in the United States (2019-2032)
  • Figure 5 Glioblastoma Multiforme (GBM) Epidemiology in Germany (2019-2032)
  • Figure 6 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Germany (2019-2032)
  • Figure 7 Glioblastoma Multiforme (GBM) Epidemiology in France (2019-2032)
  • Figure 8 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in France (2019-2032)
  • Figure 9 Glioblastoma Multiforme (GBM) Epidemiology in Italy (2019-2032)
  • Figure 10 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Italy (2019-2032)
  • Figure 11 Glioblastoma Multiforme (GBM) Epidemiology in Spain (2019-2032)
  • Figure 12 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Spain (2019-2032)
  • Figure 13 Glioblastoma Multiforme (GBM) Epidemiology in the United Kingdom (2019-2032)
  • Figure 14 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
  • Figure 15 Glioblastoma Multiforme (GBM) Epidemiology in Japan (2019-2032)
  • Figure 16 Glioblastoma Multiforme (GBM) Diagnosed and Treatable Cases in Japan (2019-2032)

The table of contents is not exhaustive; will be provided in the final report

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!